The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
AHA has released videos, social media posts and other new resources highlighting the importance of patient safety for Patient Safety Awareness Week, March 10-…
Chairperson's File
This week is Patient Safety Awareness Week. It’s an annual recognition to inspire action and raise awareness to improve the safety of our health care system…
Chairperson's File
The mission of all hospitals and health systems, regardless of size and location, is to provide quality care to patients and advance health in their…
Headline
The Centers for Disease Control and Prevention has released a five-part webinar series on its Hospital Sepsis Program Core Elements, which offer guidance to…
Perspective
Patient safety and top-notch patient care have always been the twin guide stars of our field. Hospitals and health systems have led the way in making bold…
Blog
In health care, where decisions can be life-altering and regulatory policies help shape care quality and delivery, board members play a pivotal role in…